In this cohort of BC patients with pCR after NAT, BCS was not associated with a higher risk of recurrence compared with mastectomy, and these findings support BCS as a safe treatment option for this patient population.
Abstract
Background: Optimal management of breast cancer (BC) patients with pathological complete response (pCR) after neoadjuvant therapy (NAT) remains debated. We performed a retrospective analysis to evaluate whether the extent of surgery influences survival outcomes in this patient population. Methods: Using the EUSOMA database, we retrospectively collected data of women with pCR after NAT, excluding those with BRCA1/2 mutations. The cohort was stratified by surgery type, i.e., breast-conserving surgery (BCS) or mastectomy. Relapse-free survival (RFS) and overall survival (OS) were compared using Cox regression. Results: Of 467 patients, 327 (70.0%) underwent BCS and 140 (30.0%) underwent mastectomy. Women treated with mastectomy were more likely to have multifocal tumors and advanced disease. After a median follow-up of 5.6 years, 7.3% of patients experienced BC recurrence. Axillary nodal involvement (cN+) and mastectomy were independently associated with recurrence, occurring in 11.4% of cN+ compared to 3.7% of cN0 patients (HR 3.02; 95% CI: 1.40–6.51; p = 0.005) and in 12.5% of mastectomy vs. 5.2% of BCS patients (HR 2.08; 95% CI: 1.05–4.11; p 0.035). cN+ patients also showed significantly higher mortality rates (9.4% vs. 1.6% of cN0; HR 6.16; 95%CI: 2.09–18.17; p= 0.001). However, surgery type did not impact OS. Conclusion: In this cohort of BC patients with pCR after NAT, BCS was not associated with a higher risk of recurrence compared with mastectomy. Baseline nodal involvement independently predicted recurrence and mortality; however, the type of surgery did not impact OS. These findings support BCS as a safe treatment option for this patient population.
Neoadjuvant chemotherapy (NAC) is recommended for patients with muscle-invasive bladder cancer (MIBC); however, its impact on survival outcomes remains controversial in real-world clinical settings. This retrospective observational study evaluated the effect of NAC on pathological outcomes and overall survival among pa...
I. Topcu, Bulut Dural, Ömer Faruk Yıldırım et al.· İnönü Üniversitesi Sağlık Hi...· 0 citations
Background/Objectives: The prognostic significance of residual ductal carcinoma in situ (ypTis) compared with no residual tumor in the breast (ypT0) after neoadjuvant chemotherapy (NAC) remains uncertain. We compared clinicopathological, MRI, treatment, and survival outcomes between these groups. Methods: This single-c...
O. Mermut, Berrin Yalcın, R. Gürsu et al.· Cancers· 0 citations
Objective: This study aimed to determine the pathological complete response (pCR) rate and evaluate clinicopathological factors associated with pCR in patients with breast cancer who underwent surgery after neoadjuvant chemotherapy (NAC).Materials and Methods: We retrospectively reviewed 53 women who received NAC follo...
Mehmet Ali Karatutlu, B. Ocak· Journal of Bursa Faculty of...· 0 citations
Introduction: Surgical choice in breast cancer (extent of oncologic resection and use of reconstruction) is primarily guided by oncologic safety and patient preference. Prognosis is mainly driven by tumor biology and stage, but perceived survival differences across surgical techniques persist.
Objective: To compare su...
N. Almeida, N. S. de Azevedo, F. Brenelli et al.· Mastology· 0 citations
Neoadjuvant chemotherapy has a beneficial effect on nodal status of luminal A EBC patients; constituting for skipping the formal axillary lymph node dissection (ALND) and it does not reduce the breast and axillary post-operative complications to significant values.
Mennat Allah M.Y, Abo Elqassem, M. Ahmed et al.· International Journal of Dru...· 0 citations
Introduction: Neoadjuvant chemotherapy (NAC) is a cornerstone in breast cancer treatment, particularly for locally advanced, triple-negative, and human epidermal growth factor receptor 2 (HER2)-positive disease. However, concerns remain regarding the oncologic safety of breast-conserving surgery (BCS) following NAC com...
A. D. Nascimento Lima, A. Matter, F. Cavalcante et al.· Mastology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.